Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-12-14
1998-09-01
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514866, A61K 31495
Patent
active
058011773
ABSTRACT:
The present invention is a method of treating non-insulin-dependent diabetes mellitus comprising administering to a patient in need thereof a therapeutically effective amount of at least one compound of formula (I) for a period of time of more than 6 days: ##STR1## wherein Y is O
REFERENCES:
patent: 3313813 (1967-04-01), Cragoe
patent: 4594349 (1986-06-01), Beyer, Jr.
patent: 4663322 (1987-05-01), Beyer, Jr.
patent: 4920123 (1990-04-01), Beyer, Jr.
patent: 4952582 (1990-08-01), Beyer, Jr.
patent: 5110817 (1992-05-01), Beyer, Jr.
patent: 5130333 (1992-07-01), Bergman et al.
Chemical Abstracts AN 1990:42594, Onada et al, 1990.
J. Clin Pharmacol, 1996, vol. 52, pp. 135-144, "Studies on Pyrazinoylguanidine, 1. Characterization of Metabolic Effects in Diabetic Rats", Jousif I. A-Rahim.
J. Clin Pharmacol, 1996, vol. 52, pp. 145-152, "Studies on Pyrazinoylguanidine, 2. Comparative Drug and Dose Effects on Glucose and Lipid metabolism in Streptozotocin-Induced Diabetic Rats", Jousif I. A-Rahim.
M Mosby Year Book, 1992, pp. 3-20, "Management of Diabetes Mellitus, Perspectives of Care Accros the Life Span", Robert E. Ratner.
J. Clin Pharmacol, 1994, vol. 34, pp 1234-1245, "Pyrazinoylguanidine Downregulates the Glucose Fatty-Acid Cycle in Hypertensive, Hyperinsulinemic Diabetic Patients", Elliot S. Vesell et al.; Jan. 13, 1995.
J. Clin Pharmacol, 1993, vol. 33, pp. 823-831, "Effects of Pyrazinoylguanidine on the Glucose-Fatty Acid Cycle in Normal Subjects and Patients with Non-Insulin-Dependent Diabetes Mellitus", Elliot S. Vesell et al; Sep. 27, 1993.
"Studies on Pyrazinoylguanidine", Yousif I. A-Rahim et al, pp. 1-16; In Press, 1993.
M Mosby Year Book, pp. 3-20, "Management of Diabetes Mellitus, Perspectives of Care Across the Life Span", Robert E. Ratner, 1992.
Diabetes, 1992, vol. 41, pp. 123-129, Perspectives in Diabetes, HLA and Insulin-Dependent Diabetes, Protective Perspective, Michael J. Sheehy.
The FASEB Journal, Aug. 1993, vol. 7, pp. 1092-1096, "Autoimmune Diabetes Results from Genetic Defects Manifest by Antigen Presenting Cells", David V. Serreze.
J. Clin. Invest, Mar. 1985, vol. 75, pp. 809-817, "Hyperinsulinemia", Michaela Modan et al.
Diabetics Care, Apr. 1993, vol. 16, No. 4, pp. 642-652, "Undiagnosed NIDDM: Clinical and Public Health Issues", Maureen I, Harris, Ph.D.
The American Journal of Medicine, Jan. 1981, vol. 70, pp. 142-150, "Insulin Action", Michael P. Czech, Ph.D.
Diabetes, Dec. 1976, vol. 25, No. 12, pp. 1154-1162, "The Insulin Receptor: Its Role in Insulin Resistance of Obesity and Diabetes", Jerrold M. Olefsky, M.D.
The Lancet, Apr. 13, 1963, pp. 728-789, "The Glucose Fatty-Acid Cycle".
J. Clin. Invest, Nov. 1983, vol. 72, pp. 1737-1747, "Effect of Fatty Acids on Glucose Production and Utilization in Man", Eleuterio Ferrannini et al.
Hypertension, Apr. 1991, vol. 17, No. 4., pp. 565-573, "Obesity, Glucose Intolerance, Hyperinsulinemia, and Response to Antihypertensive Drugs" Michaela Modan et al.
AJH, Apr. 1993, vol. 6, No. 4 (Supplement), pp. 123-134, "Ionis Basis of Hypertension, Insulin Resistance, Vascular Disease, and Related Disorders, the Mechanism of Syndrom X," Lawrence M. Resnick.
Journal of Clinical Endocrinology and Metabolism, 1981, vol. 53, No. 6, pp. 1256-1262, "Differential Effects of Tolbutamide on First and Second Phase Insulin Secretion in Noninsulin-Dependent Diabetes Mellitus", Michael A. Pfeifer et al.
The Journal of Biological Chemistry, 1987, vol. 262, No. 6, pp 2608-2612, "Increased Cytosolic Calcium, a Signal for Sulfonylurea-Stimulated Insulin Release from Beta Cells", T. Yap Nelson et al.
Diabetes, Sep. 1984, vol. 33, pp. 838-845, "Mechanism of Improvement in Glucose Metabolism After Chronic Glyburide Therapy" Donald C. Simonson et al.
Diabetes, Feb. 1981, vol. 30, pp. 148-162, Lilly Lecture 1980 "Insulin Resistance and Insulin Action, an In Vitro and In Vivo Perspective" Jerrold M. Olefsky.
Drugs & Aging, 1994, vol. 4, No. 6, pp. 470-490, "Treatment of Non-Insulin-Dependent Diabetes Mellitus and Its Complications, a State of the Art Review", Aldo Ilarde et al.
The Lancet, Mar. 13, 1996, "Deterioration of Glucose Tolerance in Hypertensive Patients on Prolonged Diureic Treatment", P. J. Lewis et al.
The American Journal of Medicine, Nov. 1984, vol. 77, pp. 823-827, "Elevated Hemoglobin A.sub.1c and Low-Density Lipoprotein Cholesterol Levels in Thiazide-Treated Diabetic Patients", Zachary T. Bloomgarden et al.
British Medical Journal, Jan. 20, 1979, pp. 159-161, "Beta-Adrenoceptor-Blocking Drugs and Blood Sugar Control in Diabetes Mellitus", A.D. Wright et al.
Acta Med Scand Suppl., 1983, vol. 672, pp. 69-77, ".beta.-Adrenergic Blockade and Diabetes Mellitus", Jan Ostman.
Journal of Hypertension, 1989, vol. 7, pp. 551-559, "Metabolic Effects of Diltiazem and Atenolol: Results from a Randomized, Double-Blind Study with Parallel Groups", Thomas Pollare et al.
Diabetes, Jun. 1975, vol. 24, No. 6. pp. 547-551, "Calcium Antagonists and Islet Function", G. Devis et al.
The New England Journal of Medicine, Sep. 28, 1989, vol. 321, No. 13, pp. 868-873, "A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension" Thomas Pollare et al.
Scand J. Clin. Lab Invest., 1974, vol. 34, pp. 312-315, "Hypotensive Therapy Reduces Microvascular Albumin Leakage in Insulin-Dependent Diabetic Patients with Nephropathy", H.-H. Parving et al.
The Lancet, Nov. 19, 1994, vol. 344, pp. 1383-1389, "Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S)", Scandinavian Simvastatin Survival Study Group.
Acta. Med. Scand; 1962, vol. 172, pp. 641-645, "The Effect of Nicotinic Acid on the Plasma Free Fatty Acids".
Metabolism, Feb. 1994, vol. 13, No. 2, pp. 181-189, "The Effect of Nicotinic Acid in Diabetes Mellitus", George D. Molnar et al.
Physician's Desk Reference, 1994 (Supplements for Revision), pp. 1496-1498.
Pharmacology, 1992, vol. 44, pp. 124-138, "Inhibition of Urea Transport Across Renal Tubules by Pyrazinoylguanidine and Analogs", Karl H. Beyer, Jr. et al.
J. Clin. Pharmacol; 1992, vol. 32, pp. 1128-1134, "Pyrazinoylguanidine: Antihypertensive, Hypercholesterolemic, and Renin Effects", Charles E. Chambers et al.
J. Clin. Pharmacol., 1993, vol. 33, pp. 554-561, "Contrasting Effects of Pyrazinoylguanidine and Hydrochlorothiazide in Patients with Renal Insufficiency", Karl. H. Beyer et al.
Diabetologia, 1987, vol. 30, pp. 622-626, "Insulin Suppression of Plasma-Free Fatty Acid Concentration in Normal Individuals and Patients with Type 2 (Non-Insulin-Dependent) Diabetes", A.L.M. Swislocki et al.
Pharmacological Basis of Therapeutics, 1990, 8th Edition, pp. 727-728, Goodman and Gilman.
Annu. Rev. Med., 1993, vol. 44, pp. 121-131, "Role of Insulin Resistance in Human Disease (Syndrome X): An Expanded Definition", Gerald M. Reaven, M.D.
JAMA, Dec. 11, 1967, vol. 202, No. 11, pp. 116-122, "Effects of Treatment on Morbidity in Hypertension", Veterans Administration Cooperative Study Group of Antihypertensive Agents.
American Heart Journal, Aug. 1986, vol. 112, No. 2, pp. 432-437, "The Triglyceride Issue: A View From Framingham", William P. Castelli.
JAMA, 1984, vol. 251, No. 3, pp. 365-374, "The Lipid Research Clinics Coronary Primary Prevention Trial Results, II. The Relationship of Reduction in Incidence of Coronary Heart Disease to Cholesterol Lowering", Lipid Research Clinics Program.
Pharmacology, 1996, vol. 52, pp. 135-144, "Studies on Pyrazinoylguanidine, 1. Characterization of Metabolic Effects in Diabetic Rats", Jousif I. A-Rahim.
Pharmacology, 1996, vol. 52, pp. 145-152, "Studies on Pyrazinoylguanidine, 2. Comparative Drug and Dose Effects on Glucose and Lipid Metabolism in Streptozotocin-Induced Diabetic Rats", Jousif I. A-Rahim.
M. Mosby Year Book, 1992, pp. 3-20, "Management of Diabetes Mellitus, Perspectives of Care Across the Life Span", Robert E. Ratner.
LandOfFree
Method for controlling and/or lowering serum glucose and fatty a does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for controlling and/or lowering serum glucose and fatty a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for controlling and/or lowering serum glucose and fatty a will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-270515